Urogen Pharma (NASDAQ:URGN) Stock Keeps “Buy” Rating at HC Wainwright

Urogen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $75.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 121.50% from the company’s previous close.

Several other research analysts have also issued reports on the stock. Oppenheimer raised their price target on shares of Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. Jefferies Financial Group restated a “buy” rating and set a $56.00 price target on shares of Urogen Pharma in a report on Thursday, September 10th. TD Cowen raised their price target on shares of Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. UBS Group restated a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a report on Thursday. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $52.38.

Urogen Pharma Stock Down 2.0%

Shares of URGN stock traded down $0.70 on Monday, reaching $33.86. The company had a trading volume of 262,660 shares, compared to its average volume of 822,029. The stock has a market capitalization of $1.66 billion, a PE ratio of -17.10 and a beta of 1.57. Urogen Pharma has a one year low of $16.36 and a one year high of $50.81. The business’s 50-day moving average is $43.16 and its 200 day moving average is $35.39.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The firm had revenue of $72.46 million for the quarter, compared to analysts’ expectations of $63.55 million. On average, sell-side analysts forecast that Urogen Pharma will post -0.20 earnings per share for the current fiscal year.

Insider Buying and Selling at Urogen Pharma

In other Urogen Pharma news, General Counsel Jason Smith sold 1,519 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total value of $64,618.26. Following the sale, the general counsel directly owned 53,141 shares of the company’s stock, valued at approximately $2,260,618.14. This trade represents a 2.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Chris Degnan sold 2,202 shares of the firm’s stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $36.69, for a total value of $80,791.38. Following the completion of the sale, the chief financial officer directly owned 4,561 shares in the company, valued at approximately $167,343.09. The trade was a 32.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 65,269 shares of company stock valued at $3,037,646. Company insiders own 4.80% of the company’s stock.

Institutional Trading of Urogen Pharma

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in Urogen Pharma in the second quarter valued at approximately $117,814,000. Jefferies Financial Group Inc. acquired a new stake in Urogen Pharma in the second quarter valued at approximately $80,947,000. Opaleye Management Inc. grew its holdings in Urogen Pharma by 0.7% in the second quarter. Opaleye Management Inc. now owns 1,439,996 shares of the company’s stock valued at $52,992,000 after purchasing an additional 9,996 shares during the period. SG Americas Securities LLC grew its holdings in Urogen Pharma by 20.3% in the first quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company’s stock valued at $29,808,000 after purchasing an additional 280,199 shares during the period. Finally, Bank of America Corp DE acquired a new stake in Urogen Pharma in the second quarter valued at approximately $17,506,000. 91.29% of the stock is owned by institutional investors and hedge funds.

About Urogen Pharma

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for cancers of the urinary tract. The company’s platform is based on RTGel, a proprietary reverse-thermal hydrogel designed to retain medicines in the urinary tract and provide localized treatment while limiting systemic exposure.

UroGen’s lead commercial product is JELMYTO (mitomycin), a gel-based therapy approved by the U.S. Food and Drug Administration for the primary chemoablation of low-grade upper tract urothelial cancer in adults.